| pubmed-article:19448533 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19448533 | lifeskim:mentions | umls-concept:C0021761 | lld:lifeskim |
| pubmed-article:19448533 | lifeskim:mentions | umls-concept:C0384648 | lld:lifeskim |
| pubmed-article:19448533 | lifeskim:mentions | umls-concept:C0021390 | lld:lifeskim |
| pubmed-article:19448533 | lifeskim:mentions | umls-concept:C0079189 | lld:lifeskim |
| pubmed-article:19448533 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:19448533 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:19448533 | lifeskim:mentions | umls-concept:C2698651 | lld:lifeskim |
| pubmed-article:19448533 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:19448533 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:19448533 | pubmed:dateCreated | 2009-6-10 | lld:pubmed |
| pubmed-article:19448533 | pubmed:abstractText | This review focuses on CD4+ T cells involved in the mediation of inflammatory tissue damage in murine models of inflammatory bowel diseases (IBDs). In particular, we describe the distinct roles of the homeostatic cytokine IL-7, which is essential to the maintenance of colitogenic memory CD4+ cells, and the newly discovered effector cytokine IL-17. We also discuss the close correlation between colitogenic Th17-type CD4+ T cells and inducible CD4+CD25+Foxp3+ regulatory T cells. | lld:pubmed |
| pubmed-article:19448533 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19448533 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19448533 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19448533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19448533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19448533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19448533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19448533 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19448533 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:19448533 | pubmed:issn | 1531-7056 | lld:pubmed |
| pubmed-article:19448533 | pubmed:author | pubmed-author:HibiToshifumi... | lld:pubmed |
| pubmed-article:19448533 | pubmed:author | pubmed-author:WatanabeMamor... | lld:pubmed |
| pubmed-article:19448533 | pubmed:author | pubmed-author:KanaiTakanori... | lld:pubmed |
| pubmed-article:19448533 | pubmed:author | pubmed-author:TotsukaTeruji... | lld:pubmed |
| pubmed-article:19448533 | pubmed:author | pubmed-author:HisamatsuTada... | lld:pubmed |
| pubmed-article:19448533 | pubmed:author | pubmed-author:KamadaNobuhik... | lld:pubmed |
| pubmed-article:19448533 | pubmed:author | pubmed-author:NemotoYasuhir... | lld:pubmed |
| pubmed-article:19448533 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19448533 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:19448533 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19448533 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19448533 | pubmed:pagination | 306-13 | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:meshHeading | pubmed-meshheading:19448533... | lld:pubmed |
| pubmed-article:19448533 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19448533 | pubmed:articleTitle | Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. | lld:pubmed |
| pubmed-article:19448533 | pubmed:affiliation | Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. takagast@sc.itc.keio.ac.jp | lld:pubmed |
| pubmed-article:19448533 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19448533 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19448533 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19448533 | lld:pubmed |
